A New Era for Kidney Disease: Genentech Nears Landmark Approval

SOUTH SAN FRANCISCO, CA – July 15, 2026 – Genentech, a cornerstone of the Roche Group, has secured a crucial FDA Priority Review for its drug Gazyva (obinutuzumab) as a potential treatment for primary membranous nephropathy (pMN), a debilitating autoimmune kidney disease. The decision, which sets up a potential approval by November 2026, could deliver the first-ever FDA-approved therapy for a condition that has long left patients with limited, often toxic, off-label options.

The regulatory fast-track is built on the strength of the Phase III MAJESTY study, which demonstrated Gazyva’s clear superiority over a standard immunosuppressant. The move follows a Breakthrough Therapy Designation granted in April and marks the second priority review for Gazyva in a kidney-related indication in recent months, underscoring a deliberate strategic push by the biotech giant into complex immunological disorders.

“This priority review represents an important step for patients living with primary membranous nephropathy, a chronic disease with no FDA-approved treatments,” said Levi Garraway, M.D., Ph.D., Genentech's chief medical officer. “By targeting tissue-resident B cells, Gazyva addresses an underlying cause of pMN and has the potential to help more patients achieve complete remission - a necessary step to maintaining kidney function.”

The Silent Toll of a Rare Disease

For the estimated 70,000 people in the U.S. living with pMN, the lack of an approved therapy has been a stark reality. The disease occurs when the immune system mistakenly attacks the kidneys' filtering units, the glomeruli. This assault causes massive amounts of protein to leak into the urine, leading to severe swelling, fatigue, high cholesterol, and an increased risk of blood clots. The long-term prognosis is often grim: without effective intervention, up to 40% of patients progress to end-stage renal disease within a decade, facing a future of dialysis or transplantation.

Until now, physicians have relied on a patchwork of off-label immunosuppressants, including steroids, chemotherapy agents like cyclophosphamide, and calcineurin inhibitors such as tacrolimus—the comparator drug in the MAJESTY trial. While these treatments can help some, they come with a heavy burden of potential side effects, from bone marrow suppression to further kidney toxicity. Even rituximab, another B-cell targeting antibody widely used off-label, fails to induce a lasting remission in a substantial portion of patients.

This landscape of unmet need has been a focus for patient advocates and clinicians. “Achieving complete remission is the ultimate goal,” noted one nephrologist not involved in the study. “It’s the best indicator we have for preserving long-term kidney function and preventing the slide toward failure. The current tools often fall short, forcing us to balance efficacy against significant toxicity.”

The Science of Targeted Remission

The optimism surrounding Gazyva stems from the striking results of the MAJESTY study, published in the New England Journal of Medicine. The trial showed that after two years, 36.9% of adults treated with Gazyva achieved complete remission, a state defined by a dramatic reduction in protein leakage. In stark contrast, only 5.7% of patients on tacrolimus reached the same endpoint. This represents a more than six-fold improvement and a statistically profound difference that caught the attention of the medical community when presented at the European Renal Association Congress in June.

At the heart of Gazyva's success is its mechanism. As a second-generation, glycoengineered Type II anti-CD20 monoclonal antibody, it is designed to bind to B cells—the immune cells that produce the harmful autoantibodies driving pMN—and trigger their destruction more effectively than older therapies. By directly targeting the source of the autoimmune attack, Gazyva offers a more precise approach than the broad immunosuppression of drugs like tacrolimus. This targeted strategy aims to reset the immune system without the widespread collateral damage associated with conventional treatments.

Key secondary endpoints in the MAJESTY study further bolstered the case for Gazyva, showing its superiority in achieving overall remission (both complete and partial) and hitting remission targets at earlier time points. The drug’s safety profile remained consistent with its known characteristics from use in oncology and lupus nephritis, with no new safety signals emerging in the pMN patient population.

A Strategic Expansion into Immunology

While a breakthrough for nephrology, Gazyva's success in pMN is also a testament to Genentech's broader corporate strategy. Originally approved for blood cancers like chronic lymphocytic leukemia and follicular lymphoma, Gazyva is being systematically repurposed to address high-need autoimmune diseases. This is a classic life-cycle management play, but one grounded in deep scientific rationale—leveraging a proven B-cell depletion platform to tackle a host of B-cell-mediated disorders.

This is the fourth positive Phase III study for Gazyva in immune-mediated diseases, following successful trials in lupus nephritis (REGENCY), systemic lupus erythematosus (ALLEGORY), and idiopathic nephrotic syndrome (INShore). The drug is already approved for active lupus nephritis, and its second priority review for a kidney condition in just a few months signals a powerful expansion from its oncology origins into a new pillar of growth for Roche's immunology franchise.

This strategic pivot allows the company to maximize the value of its investment in Gazyva's development while entering therapeutic areas with significant unmet needs and, consequently, strong market potential. By proving its mettle in rare and complex diseases, Genentech is solidifying its reputation as a leader in immunology, building a portfolio that extends well beyond its foundational oncology work.

Reshaping a Stagnant Market

Should Gazyva gain approval in November, it would instantly define the market as the first and only FDA-sanctioned therapy for pMN. This first-mover advantage, backed by robust clinical data showing superiority over a current standard of care, gives Genentech a commanding position. The approval would provide a clear, evidence-based option for nephrologists and offer hope to patients who are refractory to or cannot tolerate existing off-label regimens.

However, the competitive landscape is not static. The scientific community's growing understanding of pMN's pathology has fueled a pipeline of novel therapies. Competitors are exploring other mechanisms, including next-generation complement inhibitors, BTK inhibitors, and CD38-targeting antibodies. While Gazyva is poised to be the first to cross the finish line, its launch will likely herald a new era of innovation and competition in a field that has been dormant for decades. For patients and the physicians who treat them, this impending transformation is a long-overdue development, promising a future where kidney failure is no longer an inevitable outcome of a pMN diagnosis.